EA201990364A1 - КРИСТАЛЛИЧЕСКИЕ И СОЛЕВЫЕ ФОРМЫ 7-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И СПОСОБ ИХ ПОЛУЧЕНИЯ - Google Patents

КРИСТАЛЛИЧЕСКИЕ И СОЛЕВЫЕ ФОРМЫ 7-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И СПОСОБ ИХ ПОЛУЧЕНИЯ

Info

Publication number
EA201990364A1
EA201990364A1 EA201990364A EA201990364A EA201990364A1 EA 201990364 A1 EA201990364 A1 EA 201990364A1 EA 201990364 A EA201990364 A EA 201990364A EA 201990364 A EA201990364 A EA 201990364A EA 201990364 A1 EA201990364 A1 EA 201990364A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline
salt forms
pyrrolo
pyrimidines
producing
Prior art date
Application number
EA201990364A
Other languages
English (en)
Other versions
EA039655B1 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201990364A1 publication Critical patent/EA201990364A1/ru
Publication of EA039655B1 publication Critical patent/EA039655B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Настоящее изобретение относится к кристаллической и солевой формам 7H-пирроло[2,3-d]пиримидина и способу их получения, а также к применению указанных кристаллической и солевой форм для получения лекарственного средства для лечения артрита.
EA201990364A 2016-11-23 2017-11-23 КРИСТАЛЛИЧЕСКИЕ И СОЛЕВЫЕ ФОРМЫ 7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И СПОСОБ ИХ ПОЛУЧЕНИЯ EA039655B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611046683 2016-11-23
PCT/CN2017/112493 WO2018095345A1 (zh) 2016-11-23 2017-11-23 一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法

Publications (2)

Publication Number Publication Date
EA201990364A1 true EA201990364A1 (ru) 2019-10-31
EA039655B1 EA039655B1 (ru) 2022-02-22

Family

ID=62195741

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990364A EA039655B1 (ru) 2016-11-23 2017-11-23 КРИСТАЛЛИЧЕСКИЕ И СОЛЕВЫЕ ФОРМЫ 7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И СПОСОБ ИХ ПОЛУЧЕНИЯ

Country Status (16)

Country Link
US (1) US10774094B2 (ru)
EP (1) EP3511333B1 (ru)
JP (1) JP6788114B2 (ru)
KR (1) KR102136958B1 (ru)
CN (1) CN109563097B (ru)
AU (1) AU2017366375B2 (ru)
CA (1) CA3033456C (ru)
DK (1) DK3511333T3 (ru)
EA (1) EA039655B1 (ru)
ES (1) ES2882214T3 (ru)
HU (1) HUE055530T2 (ru)
MX (1) MX2019002077A (ru)
PL (1) PL3511333T3 (ru)
PT (1) PT3511333T (ru)
UA (1) UA123709C2 (ru)
WO (1) WO2018095345A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
CN113372366B (zh) * 2020-12-04 2022-08-30 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的盐、其晶型及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2326383A1 (en) * 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors
WO2001042246A2 (en) * 1999-12-10 2001-06-14 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
MX2013009972A (es) * 2011-04-08 2013-09-26 Pfizer Formas cristalinas y no cristalinas de tofacitinib y composicion farmaceutica que comprende tofacitinib y un potenciador de penetracion.
EP3318565B1 (en) 2013-12-05 2021-04-14 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
GB201410816D0 (en) * 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
CN104144337B (zh) * 2014-08-05 2016-07-06 深圳市华星光电技术有限公司 一种多视点立体显示器的图像显示方法及装置
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105566327A (zh) * 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
PL3305788T3 (pl) * 2015-05-29 2021-03-08 Wuxi Fortune Pharmaceutical Co., Ltd Inhibitor kinazy janusowej

Also Published As

Publication number Publication date
US10774094B2 (en) 2020-09-15
KR102136958B1 (ko) 2020-08-26
DK3511333T3 (da) 2021-08-02
EA039655B1 (ru) 2022-02-22
UA123709C2 (uk) 2021-05-19
US20190218231A1 (en) 2019-07-18
KR20190037291A (ko) 2019-04-05
AU2017366375B2 (en) 2020-12-03
CA3033456A1 (en) 2018-05-31
JP6788114B2 (ja) 2020-11-18
ES2882214T3 (es) 2021-12-01
HUE055530T2 (hu) 2021-12-28
CN109563097B (zh) 2021-05-14
AU2017366375A1 (en) 2019-04-18
EP3511333A4 (en) 2019-08-28
EP3511333A1 (en) 2019-07-17
PL3511333T3 (pl) 2021-12-06
JP2019535771A (ja) 2019-12-12
CA3033456C (en) 2021-03-09
MX2019002077A (es) 2019-05-15
PT3511333T (pt) 2021-08-02
CN109563097A (zh) 2019-04-02
WO2018095345A1 (zh) 2018-05-31
EP3511333B1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
MA46054A (fr) Procédé de préparation de pyrazolo[1,5-a]pyrimidines et de sels de celles-ci
EA201990519A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-7-(1-АКРИЛОИЛПИПЕРИДИН-4-ИЛ)-2-(4-ФЕНОКСИФЕНИЛ)-4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-КАРБОКСАМИДА, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЯ
CY1119487T1 (el) Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα
EA201990473A1 (ru) Полиглутамированные антифолаты и их применение
GT201600098A (es) Acrilamidas de pirrolo [2,3-d] pirimidinilo, pirrolo [2,3-b] pirazinilo y pirrolo [2,3-d] piridinilo
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
EA201790740A1 (ru) Индолкарбоксамидные соединения
EA201492176A1 (ru) Селективные ингибиторы pi3k дельта
EA201690093A1 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA201790146A1 (ru) ТИЕНО[3,2-d]ПИРИМИДИН, ФУРО[3,2-d]ПИРИМИДИН И ПИРРОЛО[3,2-d]ПИРИМИДИНЫ, ПОДХОДЯЩИЕ ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗВАННЫХ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫМ ВИРУСОМ
ECSP18026386A (es) Sales de un inhibidor de pim quinasa
EA201891772A1 (ru) Трифторацетатная соль агониста tlr7 и ее кристаллическая форма b, способы получения и использование
EA201792689A1 (ru) Производные 2-(пиразолопиридин-3-ил)пиримидина в качестве ингибиторов jak
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
EA201892729A1 (ru) Гемисульфатная соль 5,10-метилен-(6r)-тетрагидрофолиевой кислоты
EA201692255A1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах
CL2021000276A1 (es) Polimorfo cristalino del clorhidrato de 8-bromo-2-(1-metilpiperidin-4-ilamin)-4-(4-fenoxifenilamin)pirido[4,3-d]pirimidin-5(6h)-ona y método para prepararlo.
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EP3560931A4 (en) METHOD FOR PRODUCING A 7H-PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE, AND CO-CRYSTAL OF SAID DERIVATIVE
CL2018002344A1 (es) Proceso para preparar compuestos de 7h-pirrolo[2,3-d]pirimidina
EA201990364A1 (ru) КРИСТАЛЛИЧЕСКИЕ И СОЛЕВЫЕ ФОРМЫ 7-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
EA201890922A1 (ru) Циклические простоэфирные производные пиразоло[1,5-а]пиримидин-3-карбоксамида
EA201990270A1 (ru) Смеси, содержащие defi и тауратамиды, и способы их получения